Advertisement
Mayo Clinic Proceedings Home

CHADS2 Scores as a Predictor of Ischemic Stroke in Patients With Peripheral Artery Disease

Published:December 08, 2015DOI:https://doi.org/10.1016/j.mayocp.2015.09.021

      Abstract

      Objective

      To assess the predictive value of CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke) scores for stroke risk in patients with peripheral artery disease (PAD).

      Patients and Methods

      From Taiwan's National Health Insurance Research Database, we identified a total of 479 participants with non–atrial fibrillation PAD diagnoses recorded from January 1, 2002, through December 31, 2009. The CHADS2 score was used to stratify 5-year ischemic stroke risk. All participants were followed up from the date of enrollment until ischemic stroke event, death, or the end of 2009.

      Results

      The 5-year risk of ischemic stroke in the present study was 9.4%. A strong correlation was found between the PAD and CHADS2 score (CHADS2 score of 0-1, 0.4%; CHADS2 score of 2-3, 12.3%; CHADS2 score ≥4, 84.0%; area under the curve = 0.920). After adjustment, CHADS2 score was found to be positively correlated with increased risk of ischemic stroke.

      Conclusions

      Our results indicate that patients with PAD have a significantly higher risk of ischemic stroke and that the CHADS2 score can be used as an indicator of risk for ischemic stroke. Cardiovascular risk evaluation and management are suggested for patients with PAD and higher CHADS2 scores.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Muller M.D.
        • Reed A.B.
        • Leuenberger U.A.
        • Sinoway L.I.
        Physiology in medicine: peripheral arterial disease.
        J Appl Physiol. 2013; 115: 1219-1226
        • Steg P.G.
        • Bhatt D.L.
        • Wilson P.W.
        • et al.
        One-year cardiovascular event rates in outpatients with atherothrombosis.
        JAMA. 2007; 297: 1197-1206
        • Brevetti G.
        • Giugliano G.
        • Oliva G.
        • Lanero S.
        • De Maio J.I.
        • Chiariello M.
        The impact of comorbidity burden on the cardiovascular risk in the Peripheral Arteriopathy and Cardiovascular Events study.
        QJM. 2008; 101: 575-582
        • Lee W.H.
        • Hsu P.C.
        • Chu C.Y.
        • et al.
        Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan.
        PLoS One. 2014; 9: e92577
        • Gage B.F.
        • Waterman A.D.
        • Shannon W.
        • Boechler M.
        • Rich M.W.
        • Radford M.J.
        Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
        JAMA. 2001; 285: 2864-2870
        • Wang Y.F.
        • Chuang M.H.
        • Chuang T.L.
        • et al.
        CHADS2 scores in the prediction of major adverse cardiovascular events in patients with Cushing's syndrome.
        Int J Endocrinol. 2014; 2014: 138653
        • Tu H.T.
        • Campbell B.C.
        • Meretoja A.
        • et al.
        Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
        Cerebrovasc Dis. 2013; 36: 273-280
        • Cheng C.-L.
        • Lee C.-H.
        • Chen P.-S.
        • Li Y.-H.
        • Lin S.-J.
        • Yang Y.-H.K.
        Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan.
        J Epidemiol. 2014; 24: 500-507
        • Cheng C.L.
        • Kao Y.H.
        • Lin S.J.
        • Lee C.H.
        • Lai M.L.
        Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.
        Pharmacoepidemiol Drug Saf. 2011; 20: 236-242
        • Lee C.C.
        • Su Y.C.
        • Ho H.C.
        • et al.
        Risk of stroke in patients hospitalized for isolated vertigo: a four-year follow-up study.
        Stroke. 2011; 42: 48-52
        • Tsan Y.T.
        • Lee C.H.
        • Ho W.C.
        • Lin M.H.
        • Wang J.D.
        • Chen P.C.
        Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.
        J Clin Oncol. 2013; 31: 1514-1521
        • Wu C.Y.
        • Chen Y.J.
        • Ho H.J.
        • et al.
        Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection.
        JAMA. 2012; 308: 1906-1914
        • Chiang T.L.
        Taiwan's 1995 health care reform.
        Health Policy. 1997; 39: 225-239
        • Tseng C.H.
        Mortality and causes of death in a national sample of diabetic patients in Taiwan.
        Diabetes Care. 2004; 27: 1605-1609
        • Huang Y.Y.
        • Lin K.D.
        • Jiang Y.D.
        • et al.
        Diabetes-related kidney, eye, and foot disease in Taiwan: an analysis of the nationwide data for 2000-2009.
        J Formos Med Assoc. 2012; 111: 637-644
        • Chao T.F.
        • Liu C.J.
        • Chen S.J.
        • et al.
        Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation: could it refine clinical risk stratification in AF?.
        Int J Cardiol. 2014; 170: 344-349
        • Hsieh T.F.
        • Yang Y.W.
        • Lee S.S.
        • et al.
        Use of 5-α-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
        PLoS One. 2015; 10: e0119694
        • Charlson M.
        • Szatrowski T.P.
        • Peterson J.
        • Gold J.
        Validation of a combined comorbidity index.
        J Clin Epidemiol. 1994; 47: 1245-1251
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • D'Hoore W.
        • Sicotte C.
        • Tilquin C.
        Risk adjustment in outcome assessment: the Charlson comorbidity index.
        Methods Inf Med. 1993; 32: 382-387
        • Hsieh C.Y.
        • Chen C.H.
        • Li C.Y.
        • Lai M.L.
        Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database.
        J Formos Med Assoc. 2015; 114: 254-259
        • Sen S.
        • Lynch Jr., D.R.
        • Kaltsas E.
        • et al.
        Association of asymptomatic peripheral arterial disease with vascular events in patients with stroke or transient ischemic attack.
        Stroke. 2009; 40: 3472-3477
        • Meves S.H.
        • Diehm C.
        • Berger K.
        • et al.
        Peripheral arterial disease as an independent predictor for excess stroke morbidity and mortality in primary-care patients: 5-year results of the getABI study.
        Cerebrovasc Dis. 2010; 29: 546-554
        • Chen Y.C.
        • Lin H.Y.
        • Li C.Y.
        • Lee M.S.
        • Su Y.C.
        A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease.
        Kidney Int. 2014; 85: 1200-1207